Page 3 - Delaware Group Equity Fds News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sio Gene Therapies, Inc. (NASDAQ:SIOX)’s traded shares stood at 451,895 during the last session, with the company’s beta value hitting 1.7. At the close of trading, the stock’s price was $2.53, to imply an increase of 3.69% or $0.09 in intraday trading. The SIOX share’s 52-week high remains $5.74, putting it -126.88% down since that peak but still an impressive +26.48% since price per share fell to its 52-week low of $1.86. The company has a valuation of $146.2 Million, with an average of 834.2 Million shares in intraday trading volume over the past 10 days and average of 1.58 Million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Sio Gene Therapies, Inc. (SIOX), translating to a mean rating of 1.3. Of 3 analyst(s) looking at the stock, none analyst(s) give SIOX a Sell rating. 1 of those analysts rate the stock as Overweight while no one advise Hold as 2 recommend it as a Buy. None analyst(s) have given it an Underweight rating ....

Vanguard Total Stock Market Index Fund , Delaware Group Equity Fds Healthcare Fund , Sio Gene Therapies Inc , Sio Gene Therapies , Gene Therapies , Wall Street , Consonance Capital Management , Rubric Capital Management , Backdoor Way To Profit From Today , Crypto Bull Market , Delaware Group Equity Fds , Delaware Healthcare Fund , Mutual Funds , Nasdaq Siox , Io Gene Therapies Inc Siox , Iox Stock , வான்கார்ட் மொத்தம் ஸ்டாக் சந்தை குறியீட்டு நிதி , சிோ கீந் சிகிச்சைகள் இன்க் , சிோ கீந் சிகிச்சைகள் , கீந் சிகிச்சைகள் , சுவர் தெரு , ரப்ரிக் மூலதனம் மேலாண்மை , பின் கதவு வழி க்கு ப்ராஃபிட் இருந்து இன்று , கிரிப்டோ காளை சந்தை , பரஸ்பர நிதி ,